(Adnkronos) – “In the last 5 years the migraine therapeutic armamentarium has been enormously enriched with target-specific drugs. From monoclonal antibodies directed against the peptide related to the calcitonin gene (Cgrp) or its receptor, which must be administered parenterally monthly or quarterly, to the even more recent gepants, antagonists of the same receptor, which instead follow the canonical oral administration , new drugs are rapidly changing the migraine management scenario, thanks to their effectiveness and tolerability, but also by virtue of the specific methods of administration and dispensing”. Thus Cristina Tassorelli, professor of Neurology at the University of Pavia, in her speech on the occasion of the 54th National Congress of the Italian Society of Neurology (Sin) in Rome.
“And while many people with migraines who had not benefited from previous treatments now enjoy a dramatic improvement in their quality of life, research continues with a new monoclonal antibody directed against a different peptide, Pacap, which has been shown to be effective in migraine treatment in a phase 2 study. The good news for doctors and patients therefore continues,” he concludes.
